2024-09-02 - Analysis Report
## REGN Stock Analysis Report

**Company Overview:** Regeneron Pharmaceuticals, Inc. is a biotechnology company focused on the discovery, development, and commercialization of life-transforming medicines for serious diseases.

**1. Performance Comparison:**

* **REGN Cumulative Return:** 159.56%
* **S&P 500 (VOO) Cumulative Return:** 89.66%
* **Performance Difference:** 69.9%
* **Relative Performance:** 95.82%

This indicates that REGN has significantly outperformed the S&P 500 over the period considered, with its current relative performance ranking at the 95.82nd percentile of its historical performance range. 

**2. Recent Price Movement:**

* **Closing Price:** $1184.69
* **5-day Moving Average:** $1192.81
* **20-day Moving Average:** $1158.3
* **60-day Moving Average:** $1090.18

The current price is below the 5-day and 20-day moving averages, suggesting a potential short-term downtrend. However, it is still above the 60-day moving average, indicating long-term bullish momentum.

**3. Technical Indicators:**

* **RSI:** 73.51
* **PPO:** -0.17
* **Delta_Previous_Relative_Divergence:** -4.18 (Negative, indicating short-term decline)
* **Expected_Return:** 3.13% (Maximum expected return over 5 years)

The RSI indicates the stock is currently in the overbought territory. The PPO suggests a weakening short-term momentum. The negative delta_previous_relative_divergence further reinforces the short-term decline. However, the positive expected return indicates potential for future growth.

**4. Recent Earnings and Outlook:**

| Date | EPS | Revenue |
|---|---|---|
| 2024-08-01 | 13.25 | 3.55 B$ |
| 2024-05-02 | 6.7 | 3.15 B$ |
| 2023-11-02 | 9.48 | 3.36 B$ |
| 2023-08-03 | 9.05 | 3.16 B$ |
| 2024-08-01 | 9.05 | 3.16 B$ |

The most recent earnings report shows that REGN surpassed earnings expectations for the quarter ending August 2024. The company's revenue also exceeded projections. This positive earnings performance reflects strong demand for their products and a healthy business outlook. 

**5. Overall Analysis:**

REGN has significantly outperformed the S&P 500 in the past, showing strong long-term growth potential. However, current technical indicators suggest short-term weakness and an overbought condition. Despite this, recent strong earnings performance and positive outlook indicate a favorable long-term prospect for the company. Investors should consider the current market conditions and individual risk tolerance when making investment decisions.

**6. Conclusion:**

REGN is a promising company with a track record of strong performance. However, its current market position and technical indicators suggest a potential short-term downturn. Investors should consider the current market conditions, earnings performance, and long-term growth prospects before making any investment decisions. 
